Biosimilar Product. Upon the first entry in a given country of a Biosimilar Product, the royalties in such country for such Product shall be reduced as follows:
Appears in 3 contracts
Samples: Confidential Treatment Requested (Pieris Pharmaceuticals, Inc.), Confidential Treatment Requested (Pieris Pharmaceuticals, Inc.), Collaboration and License Agreement (Pieris Pharmaceuticals, Inc.)